MedPath

KANGABIO AUSTRALIA PTY LTD

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:1
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy with Envafolimab in Patients with Advanced or Metastatic Solid Tumors.

Phase 1
Active, not recruiting
Conditions
Advanced or Metastatic Solid Tumors
Interventions
Drug: KGX101- Cohort 3
Drug: KGX101- Cohort -1
Drug: KGX101- Cohort 2
Drug: KGX101- Cohort 5
Drug: KGX101- Cohort 4
Drug: KGX101- Cohort 1
First Posted Date
2023-10-10
Last Posted Date
2025-02-07
Lead Sponsor
Kangabio AUSTRALIA LTD PTY
Target Recruit Count
54
Registration Number
NCT06074497
Locations
🇦🇺

Pindara Private Hospital, Benowa, Queensland, Australia

🇦🇺

Sunshine Coast University Private Hospital, Birtinya, Queensland, Australia

🇦🇺

Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia

News

No news found
© Copyright 2025. All Rights Reserved by MedPath